FDA
-
-
-
-
-
-
-
KalVista reports interim Phase 3 data for pediatric HAE treatment
-
-
-
-
-
-
-
KalVista gets positive EU opinion for hereditary angioedema drug
-
-
-
-
-
-
-
Kalvista Pharmaceuticals Inc (KALV) PT Raised to $20 at Leerink Partners
-
-
-
-
-
-
-
KalVista Pharmaceuticals (KALV) falls after FDA chief said to have sought rejection of drug
-
-
-
-
-
-
-
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
-
-
-
-
-
-
-
KalVista Pharmaceuticals (KALV) Enters Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
-
-
-
-
-
-
-
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
-
323,454 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

